CORZ Nasdaq Finance Services Financials FY2020βFY2025
Core Scientific, Inc./tx had $319M of revenue in fiscal 2025, down 37.5% on the year before. Over five years, revenue changed +39.5% a year on average.
Last close Β· Oct 23, 2026
$13.10
0.8%Hi! I read Core Scientific, Inc./txβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β37.5%
No. Sales fell 37.5% last year.
Does it make a profit?
β90.5%
No. It lost money last year.
Does profit turn into cash?
β141.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Core Scientific, Inc./tx did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 28, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 6, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 2, 2026 | Q4 '25 | After the market closes | 8-K β |
| Oct 24, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 8, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 7, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 26, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 6, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Core Scientific, Inc./tx had $319M of revenue in fiscal 2025, down 37.5% on the year before. Over five years, revenue changed +39.5% a year on average. Its operating margin was β77.0%, down 49.2Β pts: of every 100 in sales, about β77 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Core Scientific, Inc./tx lost $289M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$451M in fiscal 2025, β141.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Core Scientific, Inc./tx owes $750M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Core Scientific, Inc./tx can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $118M | $15.9M | $50.4M | $836M | $311M |
| Debt incl. finance leases | β | β | β | β | $1.1B |
| Current ratio | 2.4x | 0.5x | 0.2x | 6.7x | 1.1x |
| Quick ratio | 2.4x | 0.5x | 0.2x | 6.7x | 1.1x |
| Total assets | $2.4B | $808M | $712M | $1.5B | $2.3B |
| Total liabilities | $1.1B | $1.2B | $1.3B | $2.4B | $3.3B |
| Shareholders' equity | $1.3B | β$409M | β$597M | β$943M | β$963M |
| Net debt (β = net cash) | β | β | β | β | $750M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Core Scientific, Inc./tx passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 3 / 8 | 4 / 8 | 4 / 8 | 3 / 8 |
| Accruals ratio | 77,060.0% | 8.5% | β144.9% | β41.0% | β135.3% | β29.7% |
| Altman Z'' | β | 2.84 | β27.50 | β15.08 | β6.16 | β6.45 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $60.3M | $544M | $640M | $502M | $511M | $319M |
| Gross profit | $9.4M | $239M | $8.4M | $123M | $121M | $37.9M |
| Research and development | $5.3M | $7.7M | $27.0M | $7.2M | $11.8M | β |
| Operating income | β$6.3M | $131M | β$2.1B | $9.0M | β$142M | β$246M |
| Pretax income | β$12.2M | $63.1M | β$2.2B | β$246M | β$1.4B | β$288M |
| Income tax | $0.0M | $15.8M | β$17.1M | $0.7M | $0.9M | $0.6M |
| Net income | β$12.2M | $47.3M | β$2.1B | β$246M | β$1.4B | β$289M |
| Net income to common | β$22.7M | $47.3M | β$2.1B | β$246M | β$1.2B | β$281M |
| Diluted EPS | β$0.14 | $0.20 | β$6.30 | β$0.65 | β$4.87 | β$0.88 |
| Diluted shares | 0.16B | 0.23B | 0.34B | 0.38B | 0.26B | 0.32B |
| Cash flow | ||||||
| Cash from operations | β$23.8M | β$56.7M | $205M | $65.1M | $42.9M | $278M |
| Capital expenditure | $0.0M | $0.0M | $384M | $16.2M | $95.0M | $729M |
| Free cash flow | β$23.8M | β$56.7M | β$179M | $49.0M | β$52.1M | β$451M |
| Depreciation and amortization | $9.4M | $33.4M | $225M | $96.0M | $113M | $68.9M |
| Stock-based compensation | $3.0M | $38.9M | $183M | $58.9M | $51.9M | $98.2M |
| Share buybacks | β | β | $31.6M | $0.0M | $0.0M | β |
| Dividends and buybacks | β | β | $31.6M | $0.0M | $0.0M | β |
| Balance sheet | ||||||
| Cash and short-term investments | $8.7M | $118M | $15.9M | $50.4M | $836M | $311M |
| Total debt | β | β | β | β | β | $1.1B |
| Finance lease liabilities | β | β | $0.0M | $55.5M | $1.7M | $0.8M |
| Current assets | β | $757M | $85.1M | $97.0M | $904M | $896M |
| Current liabilities | $0.0M | $320M | $187M | $488M | $135M | $781M |
| Property and equipment, net | β | β | β | β | $433M | $1.3B |
| Goodwill | β | $1.1B | $0.0M | $0.0M | β | β |
| Intangible assets | β | $8.2M | $1.7M | $2.2M | β | $1.1M |
| Total assets | $0.0M | $2.4B | $808M | $712M | $1.5B | $2.3B |
| Total liabilities | $0.0M | $1.1B | $1.2B | $1.3B | $2.4B | $3.3B |
| Preferred stock | β | β | β | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $89.2M | $1.3B | β$409M | β$597M | β$943M | β$963M |
| Margins | ||||||
| Gross margin | 15.6% | 43.9% | 1.3% | 24.6% | 23.7% | 11.9% |
| Operating margin | β10.5% | 24.2% | β329.5% | 1.8% | β27.8% | β77.0% |
| EBITDA margin | 5.1% | 30.3% | β294.3% | 20.9% | β5.7% | β55.4% |
| Net margin | β20.2% | 8.7% | β335.2% | β49.1% | β281.6% | β90.5% |
| FCF margin | β39.4% | β10.4% | β27.9% | 9.7% | β10.2% | β141.3% |
| Returns | ||||||
| Return on capital employed | β43,335.6% | 6.2% | β339.8% | 4.0% | β10.6% | β15.7% |
| Return on equity | β13.7% | 6.6% | β460.7% | β | β | β |
| Return on assets | β81,373.3% | 3.9% | β132.2% | β32.4% | β131.4% | β15.1% |
| Return on tangible equity | β25.4% | 17.1% | β | β | β | β |
| Growth | ||||||
| Revenue growth | β | 802.7% | 17.6% | β21.5% | 1.6% | β37.5% |
| Net income growth | β | β | β4,636.5% | β | β | β |
| EPS growth | β | β | β3,250.0% | β | β | β |
| FCF growth | β | β | β | β | β206.4% | β |
| Share count change | β | 48.0% | 46.0% | 11.5% | β32.7% | 24.3% |
| Financial health | ||||||
| Current ratio | β | 2.4x | 0.5x | 0.2x | 6.7x | 1.1x |
| Quick ratio | β | 2.4x | 0.5x | 0.2x | 6.7x | 1.1x |
| Capital allocation | ||||||
| Capex / revenue | 0.0% | 0.0% | 60.0% | 3.2% | 18.6% | 228.5% |
| Stock comp / revenue | 5.0% | 7.2% | 28.6% | 11.7% | 10.2% | 30.8% |
| Payouts / FCF | β | β | β | 0.0% | β | β |
| Quality scores | ||||||
| Piotroski F-score | β | 3.0 | 3.0 | 4.0 | 4.0 | 3.0 |
| Altman Z'' | β | 2.8 | β27.5 | β15.1 | β6.2 | β6.4 |
| Accruals ratio | 77,060.0% | 8.5% | β144.9% | β41.0% | β135.3% | β29.7% |
Source: SEC EDGAR XBRL filings (CIK 0001839341). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
